STANDARD BIOTOOLS INC. - COMMON STOCK

Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time

10 May 2021 12:30:00 By Nasdaq GlobeNewswire

Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

06 May 2021 15:05:02 By Nasdaq GlobeNewswire

Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

06 May 2021 07:30:01 By Nasdaq GlobeNewswire

Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results

08 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay

01 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results

10 Feb 2021 15:05:01 By Nasdaq GlobeNewswire

Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China

10 Feb 2021 15:02:00 By Nasdaq GlobeNewswire

George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

10 Feb 2021 15:02:00 By Nasdaq GlobeNewswire

NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19

09 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

04 Feb 2021 15:02:00 By Nasdaq GlobeNewswire

Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

26 Jan 2021 07:30:01 By Nasdaq GlobeNewswire

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

21 Jan 2021 15:05:00 By Nasdaq GlobeNewswire

Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results

07 Jan 2021 15:02:00 By Nasdaq GlobeNewswire

New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy

05 Jan 2021 07:30:01 By Nasdaq GlobeNewswire